Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Res ; 143: 17-26, 2019 05.
Article in English | MEDLINE | ID: mdl-30862604

ABSTRACT

Recent data have demonstrated that triple negative breast cancer (TNBC) with high glucocorticoid receptor (GR) expression are associated to therapy resistance and increased mortality. Given that GR alternative splicing generates mainly GRα, responsible of glucocorticoids action, we investigated its role in the regulation of RACK1 (Receptor for Activated C Kinase 1), a scaffolding protein with a GRE (Glucocorticoid Response Element) site on its promoter and involved in breast cancer cells migration and invasion. We provide the first evidence that GRα transcriptionally regulates RACK1 by a mechanism connected to SRSF3 splicing factor, which promotes GRα, essential for RACK1 transcriptional regulation and consequently for cells migration. We also establish that this mechanism can be positively regulated by cortisol. Hence, our data elucidate RACK1 transcriptional regulation and demonstrate that SRSF3 involvement in cells migration implies its role in controlling different pathways thus highlighting that new players have to be considered in GR-positive TNBC.


Subject(s)
Hydrocortisone/pharmacology , Neoplasm Proteins , Receptors for Activated C Kinase , Receptors, Glucocorticoid , Serine-Arginine Splicing Factors , Triple Negative Breast Neoplasms , Alternative Splicing , Cell Line, Tumor , Cell Movement/drug effects , Humans , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , RNA, Small Interfering/genetics , Receptors for Activated C Kinase/genetics , Receptors for Activated C Kinase/metabolism , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Serine-Arginine Splicing Factors/genetics , Serine-Arginine Splicing Factors/metabolism , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/metabolism , Triple Negative Breast Neoplasms/pathology , Wound Healing/drug effects
2.
Cell Rep ; 22(10): 2690-2701, 2018 03 06.
Article in English | MEDLINE | ID: mdl-29514097

ABSTRACT

Glucocorticoids (GCs) are master regulators of systemic metabolism. Intriguingly, Cushing's syndrome, a disorder of excessive GCs, phenocopies several menopause-induced metabolic pathologies. Here, we show that the glucocorticoid receptor (GR) drives steatosis in hypogonadal female mice because hepatocyte-specific GR knockout mice are refractory to developing ovariectomy-induced steatosis. Intriguingly, transcriptional profiling revealed that ovariectomy elicits hepatic GC hypersensitivity globally. Hypogonadism-induced GC hypersensitivity results from a loss of systemic but not hepatic estrogen (E2) signaling, given that hepatocyte-specific E2 receptor deletion does not confer GC hypersensitivity. Mechanistically, enhanced chromatin recruitment and ligand-dependent hyperphosphorylation of GR underlie ovariectomy-induced glucocorticoid hypersensitivity. The dysregulated glucocorticoid-mediated signaling present in hypogonadal females is a product of increased follicle-stimulating hormone (FSH) production because FSH treatment in ovary-intact mice recapitulates glucocorticoid hypersensitivity similar to hypogonadal female mice. Our findings uncover a regulatory axis between estradiol, FSH, and hepatic glucocorticoid receptor signaling that, when disrupted, as in menopause, promotes hepatic steatosis.


Subject(s)
Estrogens/deficiency , Fatty Liver/metabolism , Fatty Liver/pathology , Receptors, Glucocorticoid/metabolism , Animals , Chromatin/metabolism , Cushing Syndrome/metabolism , Estradiol/deficiency , Estradiol/metabolism , Female , Follicle Stimulating Hormone/pharmacology , Ligands , Lipogenesis/drug effects , Liver/drug effects , Liver/metabolism , Liver/pathology , Metabolic Networks and Pathways/drug effects , Mice, Inbred C57BL , Ovariectomy , Ovary/metabolism , Ovary/pathology , Phosphorylation/drug effects , Phosphoserine/metabolism , Signal Transduction/drug effects , Transcription, Genetic/drug effects
3.
Int J Mol Sci ; 18(7)2017 Jul 06.
Article in English | MEDLINE | ID: mdl-28684670

ABSTRACT

Immunosenescence defines the decline in immune function that occurs with aging. This has been associated, at least in part, with defective cellular signaling via protein kinase C (PKC) signal transduction pathways. Our data suggest reduced PKC activation and consequently reduced response to lipopolysaccharide (LPS) stimulation and cytokine release. The lack of PKC activation seems to be dependent on the reduced expression of the receptor for activated C kinase 1 (RACK1), a scaffolding protein involved in multiple signal transduction cascades. The defective expression of RACK1 may be dependent on age-related alteration of the balance between the adrenal hormones cortisol and dehydroepiandrosterone (DHEA). DHEA levels reduce with aging, while cortisol levels remain substantially unchanged, resulting in an overall increase in the cortisol:DHEA ratio. These hormonal changes are significant in the context of RACK1 expression and signaling function because DHEA administration in vivo and in vitro can restore the levels of RACK1 and the function of the PKC signaling cascade in aged animals and in human cells. In contrast, there is evidence that cortisol can act as a negative transcriptional regulator of RACK1 expression. The rack1 gene promoter contains a glucocorticoid responsive element that is also involved in androgen signaling. Furthermore DHEA may have an indirect influence on the post-transcriptional regulation of the functions of the glucocorticoid receptor. In this review, we will examine the role of the hormonal regulation of rack1 gene transcriptional regulation and the consequences on signaling and function in immune cells and immunosenescence.


Subject(s)
Aging/immunology , Androgens/metabolism , Glucocorticoids/metabolism , Neoplasm Proteins/metabolism , Receptors for Activated C Kinase/metabolism , Signal Transduction , Animals , Humans , Neoplasm Proteins/genetics , Receptors for Activated C Kinase/genetics , Transcriptional Activation
4.
Toxicol Appl Pharmacol ; 325: 37-47, 2017 06 15.
Article in English | MEDLINE | ID: mdl-28412309

ABSTRACT

We recently demonstrated the existence of a complex hormonal balance between steroid hormones in the control of RACK1 (Receptor for Activated C Kinase 1) expression and immune activation, suggesting that this scaffold protein may also be targeted by endocrine disrupting chemicals (EDCs). As a proof of concept, we investigated the effect of the doping agent nandrolone, an androgen receptor (AR) agonist, and of p,p'DDT (dichlorodiphenyltrichloroethane) and its main metabolite p,p'DDE (dichlorodiphenyldichloroethylene), a weak and strong AR antagonist, respectively, on RACK1 expression and innate immune response. In analogy to endogenous androgens, nandrolone induced a dose-related increase in RACK1 transcriptional activity and protein expression, resulting in increased LPS-induced IL-8 and TNF-α production and proliferation in THP-1 cells. Conversely, p,p'DDT and p,p'DDE significantly decrease RACK1 expression, LPS-induced cytokine production and CD86 expression; with p,p'DDE exerting a stronger repressor effect than p,p'DDT, consistent with its stronger AR antagonistic effect. These results indicate that RACK1 could be a relevant target of EDCs, responding in opposite ways to agonist or antagonist of AR, representing a bridge between the endocrine system and the innate immune system.


Subject(s)
Endocrine Disruptors/toxicity , GTP-Binding Proteins/metabolism , Immunity, Innate/drug effects , Lymphocytes/drug effects , Neoplasm Proteins/metabolism , Receptors, Cell Surface/metabolism , Androgen Antagonists/toxicity , Androgens/toxicity , B7-2 Antigen/metabolism , Cell Line , Cell Proliferation/drug effects , DDT/toxicity , Dichlorodiphenyl Dichloroethylene/toxicity , GTP-Binding Proteins/genetics , Humans , Interleukin-8/metabolism , Lipopolysaccharides/pharmacology , Lymphocyte Activation/drug effects , Lymphocytes/enzymology , Lymphocytes/immunology , Nandrolone/toxicity , Neoplasm Proteins/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors for Activated C Kinase , Receptors, Androgen/drug effects , Receptors, Androgen/metabolism , Receptors, Cell Surface/genetics , Receptors, Glucocorticoid/drug effects , Receptors, Glucocorticoid/metabolism , Signal Transduction/drug effects , Transcription, Genetic/drug effects , Transfection , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation
5.
Pharmacol Res ; 120: 180-187, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28373129

ABSTRACT

Dehydroepiandrosterone (DHEA) can counteract the activity of cortisol by modulating the glucocorticoid receptor ß (GRß) expression and antagonizing the binding of GRα to the glucocorticoid responsive element (GRE) in RACK1 (Receptor for Activated C Kinase 1) promoter. These observations are important in the context of immunosenescence and can be extended to recognize a complex hormonal balance in the control of GR isoform expression and consequently in the expression of GR responsive genes. To elucidate the mechanism of DHEA on GR alternative splicing, we investigated its possible involvement in the expression of proteins such as the Serine/arginine (SR)-Rich Splicing Factors (SRSF) regulating GR splicing, specifically SRSF9 and SRSF3 also known as SRp30c and SRp20 respectively. We demonstrated that DHEA can induce the up-regulation of GR mRNA which is preferentially directed toward the ß isoform. The effect is due to an increase in expression of the splicing factor SRSF9. On the other hand cortisol up-regulated SRSF3, the splicing factor promoting GRα isoform. We demonstrated that DHEA and cortisol modulate SRSF9 and SRSF3 in a different way and our data suggest that the anti-glucocorticoid effect of DHEA, among other mechanisms, is also exerted by modulating the expression of proteins involved in the splicing of the GR pre-mRNA.


Subject(s)
Alternative Splicing , Dehydroepiandrosterone/metabolism , Hydrocortisone/metabolism , Receptors, Glucocorticoid/genetics , Serine-Arginine Splicing Factors/genetics , Cell Line , Gene Expression Regulation , Gene Silencing , Humans , Protein Isoforms/genetics , RNA, Messenger/genetics , Serine-Arginine Splicing Factors/metabolism , Spliceosomes/genetics , Spliceosomes/metabolism , Up-Regulation
6.
Cell Signal ; 35: 264-271, 2017 07.
Article in English | MEDLINE | ID: mdl-28192162

ABSTRACT

The Receptor for Activated C Kinase 1 (RACK1) is a scaffold protein for different kinases and membrane receptors. RACK1 can shuttle proteins to their sites of action, facilitate cross-talk among distinct signaling pathways or recruit other signaling proteins into the complexes. Therefore, it is a key mediator of various pathways and is involved in various biological events including development, immune response, brain activity and cancer. Because of its importance, it is of extreme significance to understand the transcriptional mechanisms governing its expression. The identification of regulatory elements in the promoter of RACK1 shed some light on its transcriptional modulation in physiological and pathological context. Literature data support the existence of a complex hormonal balance, between glucocorticoids and androgens, in the control of RACK1 expression due to specific and complex interactions on the RACK1 promoter. These and other informations suggest that a better understanding of RACK1 transcriptional regulation is essential to unravel its role. Furthermore, the modulation of its expression in physiological or pathological conditions may be of interest in different context, such as aging and cancer.


Subject(s)
Aging/genetics , Neoplasm Proteins/genetics , Neoplasms/genetics , Receptors for Activated C Kinase/genetics , Transcription, Genetic , Aging/pathology , Gene Expression Regulation , Humans , Neoplasms/pathology , Promoter Regions, Genetic , Receptors, Cell Surface , Regulatory Sequences, Nucleic Acid/genetics , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL